<DOC>
	<DOCNO>NCT01267188</DOCNO>
	<brief_summary>The purpose study assess safety efficacy three dos ( 12.5 , 25 , 50 mg ) NBI-98854 treatment symptom tardive dyskinesia ( TD ) subject schizophrenia schizoaffective disorder .</brief_summary>
	<brief_title>Efficacy Safety NBI-98854 Subjects With Tardive Dyskinesia</brief_title>
	<detailed_description>This Phase 2 , open-label , dose titration study assess efficacy safety three daily ( q.d . ) dose ( 12.5 , 25 , 50 mg ) NBI-98854 administer daily 12 day consist three treatment period 4 day ( Periods 1 , 2 , 3 ) . The start dose 12.5 mg q.d . ( Period 1 ) , dose escalate 25 mg q.d . ( Period 2 ) 50 mg q.d . ( Period 3 ) base upon subject 's ability tolerate NBI-98854 . Progression next dose level base upon subject 's ability tolerate previous dose Investigator 's review adverse event safety data . For subject tolerate dose increase , dose may decrease dose previously administer ( i.e. , 25 mg 12.5 mg , 50 mg 25 mg ) continue dose remainder study treatment . Up 10 medically stable subject schizophrenia schizoaffective disorder moderate severe symptom TD enrol outpatient .</detailed_description>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<criteria>Males female ( nonchildbearing potential ) age 18 65 year ( inclusive ) . Have moderate severe Tardive Dyskinesia symptom ( Total AIMS score least 9 ) Have clinical diagnosis schizophrenia schizoaffective disorder . Receiving stable dose antipsychotic medication minimum 30 day stable psychiatric status . Doses concurrent medication condition treat stable minimum 30 day expect remain stable study . Are good general health expect complete clinical study design . Have body mass index ( BMI ) 18 38 kg/m^2 . Have adequate hearing , vision , language skill perform procedure specify protocol . Have active clinically significant unstable medical condition within 1 month ( 30 day ) prior screen . Have history substance dependence substance ( drug ) alcohol abuse within 3 month study start . Have know history neuroleptic malignant syndrome . Have significant risk suicidal violent behavior . Receiving medication treatment Tardive Dyskinesia Receiving exclude concomitant medication specify protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>